Andere Sprachen CanSino Biologics Inc.

Aktien

A2PGFW

CNE100003F01

6185

Pharmazeutika

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:32 20.09.2024			% 5 Tage	% 1. Jan.
21,25 ^HKD	+5,99 %		+6,25 %	-9,77 %

29.08.	CanSino Biologics Inc. meldet Ergebnis für das am 30. Juni 2024 endende Halbjahr	CI
27.06.	CanSino Biologics Inc. stimmt der Wahl von Chi Shing LI als nicht-geschäftsführendes Verwaltungsratsmitglied zu	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

CanSinoBIO Reports Outstanding H1 2024 Performance	29.08.
CanSino Biologics Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	29.08.
Certain A Shares of CanSino Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2024.	13.08.
CanSino Biologics Inc. Approves Election of Chi Shing LI as Non-Executive Director	27.06.
CanSino Biologics : CanSinoBIO Executives Talk with WHO Experts on the Development Progress of Polio Vaccines	25.06.
Cansino Biologics' Senior Management to Boost Stakeholding	24.06.
Indonesia ramps up fight against tuberculosis amid concerns on economic impact	10.06.
CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	31.05.
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	21.05.
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	29.04.
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	26.04.
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	22.04.
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	22.04.
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	22.04.
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough	27.03.
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia	25.03.
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21.03.
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20.03.
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	14.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

CanSino Biologics über AstraZeneca-Deal und Ergebnis

Am 31. August 2023 um 12:08 Uhr